Drugs, Bruno (Cdmo): “Our third-party companies excellence in the EU”

“The 21 companies that are part of the Cdmo Group – Farmindustria’s pharmaceutical manufacturing specialists produce for large national and international groups with an export that reaches 80-90% of production, in line with that of the pharmaceutical industry as a whole. we have very high quality standards, approved and recognized by the European and American regulatory authorities. Giorgio Bruno, confirmed as president of the Cdmo Group for the two-year period 2021-2023, affirms this to Adnkronos Salute. to represent an excellence in Europe and are specialized in the production, control and development of drugs for companies with marketing authorization. “The value of pharmaceutical production in the Cdmo sector is 2.3 billion in total in Italy . And the total number of employees is 11,945 “, reports Bruno.” During the pandemic – he underlines – our companies, like all those in the pharmaceutical industry, have never stopped. We have organized ourselves to guarantee all employees working conditions adequate to what was the external situation, respecting the protocols and the various Dpcm. And so we organized the work shifts of the staff. In addition, we have kept the offer of all traditional drugs used for Covid-19. We are talking about steroids, heparins, antibiotics. But we also worked on vaccines (filling, packaging and distribution) and on monoclonal antibodies “, adds Bruno.” 2020 – he remarks – was therefore a year for the sector that saw the sector committed to offering a very diversified range of products and all high-tech “. In his fourth term at the helm of CDMO, president Bruno is keen to specify that, between now and 2023, the objectives are:” Maintain the competitive advantage that our companies have achieved. Always use cutting-edge technologies, continue to invest in machinery and systems, adopting typical Industry 4.0 solutions. To confirm more and more what our capacity is in terms of technology transfer, and to have the possibility of attracting to Italy the productions that are now delocalized abroad. Because we offer great quality in both products and services. And another thing I like to emphasize is that we are much more flexible in responding to customer questions in a very short time “. The CDMO is an integral part of pharmaceutical production,” because – concludes Bruno – well equipped to make new drugs. For me it is an honor to be able to represent him. And it is precisely for this reason that I will immediately commit myself to bring the value of the CDM to the attention of the Community institutions in Brussels “.